Emmett Chapital
Cardiovascular Disease · New Orleans, LANPI 1982788923
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Pfizer at 51.9% of the total. Reporting peaked in 2022 at $7,129 and has fallen 81.8% since, to $1,297 in 2025.
Across 319 payments — averaging $40.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Novartis$2K
- Merck$794
- E.r. Squibb & Sons, L.L.C.$363
- Bridgebio Pharma, Inc.$341
- Alnylam Pharmaceuticals Inc.$295
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$6,05047%
- Food & beverage$6,67852%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 27 | $6,624 |
| Novartis | 97 | $1,506 |
| Merck | 40 | $794 |
| E.r. Squibb & Sons, L.L.C. | 16 | $363 |
| Bridgebio Pharma, Inc. | 3 | $341 |
| Alnylam Pharmaceuticals Inc. | 8 | $295 |
| Edwards Lifesciences | 6 | $283 |
| Lexicon Pharmaceuticals, Inc. | 13 | $278 |
| Amgen | 19 | $258 |
| Boehringer Ingelheim | 12 | $233 |
| Kowa Pharmaceuticals America, Inc. | 13 | $222 |
| AstraZeneca | 12 | $193 |
| Johnson & Johnson | 4 | $176 |
| Lilly USA, LLC | 3 | $162 |
| Abiomed | 2 | $148 |
| Recordati_rare_diseases_inc. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 6 | $104 |
| Novo Nordisk | 5 | $102 |
| Arbor Pharmaceuticals, Inc. | 7 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $64 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Medicure Pharma Inc. | 2 | $46 |
| Gilead | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $39 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Akcea Therapeutics, Inc. | 1 | $27 |
| Medicomp Inc | 1 | $27 |
| Boston Scientific | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,760 in reported general payments places this provider in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 123 | $159,978 |
| EliquisApixaban | 60 | $68,132 |
| JardianceEmpagliflozin | 27 | $35,582 |
| Repatha SureclickEvolocumab | 45 | $35,409 |
| XareltoRivaroxaban | 27 | $27,527 |
| VascepaIcosapent Ethyl | 19 | $12,277 |
| LivaloPitavastatin Calcium | 21 | $10,575 |
| Ranolazine ErRanolazine | 97 | $7,573 |
| Rosuvastatin Calcium | 482 | $7,313 |
| Clonidine | 35 | $7,240 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 257 | $5,700 |
| Metoprolol Succinate | 324 | $3,795 |
| Nebivolol Hcl | 56 | $3,119 |
| Carvedilol | 369 | $3,017 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 28 | $2,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,506 | $159,978123 claims |
| PfizerEliquis | $6,624 | $68,13260 claims |
| Boehringer IngelheimJardiance | $233 | $35,58227 claims |
| Johnson & JohnsonXarelto | $176 | $27,52727 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $222 | $10,57521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Yvonne GillilandNew Orleans$13K
- Frank WilklowNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.